

Fig. E-1

Platelet counts in platelet-rich plasma (PRP), platelet-poor plasma (PPP), and whole blood following platelet concentration. The values represent the mean and standard error of the mean for six donors. \* $p \leq 0.05$  for platelet-rich plasma compared with platelet-poor plasma or blood.




Fig. E-2

Concentrations of active (A) and latent (B) transforming growth factor beta-1 (TGF- $\beta$ 1) in platelet-rich plasma (PRP), platelet-poor plasma (PPP), and whole blood before and after platelet activation with thrombin. The values represent the mean and standard error of the mean for six donors. \* $p < 0.05$  for platelet-poor plasma or blood compared with platelet-rich plasma. # $p < 0.05$  for before thrombin activation compared with after thrombin activation.




Fig. E-3

Concentrations of platelet-derived growth factor-AA (PDGF-AA) (Panel A), PDGF-BB (Panel B), and PDGF-AB (Panel C) in platelet-rich plasma (PRP), platelet-poor plasma (PPP), and whole blood before and after thrombin activation. The values represent the mean and standard error of the mean for six donors. \* $p < 0.05$  for platelet-poor plasma or blood compared with platelet-rich plasma; # $p < 0.05$  for before thrombin activation compared with after thrombin activation.

**TABLE E-1** Implant groups used in this study. Two different batches of demineralized bone matrix, DBM-1 and DBM-2, were used. Platelet-rich plasma (PRP) was prepared from blood donated by six healthy men. Each formulation was tested bilaterally in four mice, resulting in eight implants.

Treatment Group	DBM Donor	PRP Donor	Implant
1	1		DBM-1
2	2		DBM-2
3	1	1	DBM-1 + PRP 1
4	1	2	DBM-1 + PRP 2
5	1	3	DBM-1 + PRP 3
6	1	4	DBM-1 + PRP 4
7	1	5	DBM-1 + PRP 5
8	1	6	DBM-1 + PRP 6
9	2	1	DBM-2 + PRP 1
10	2	2	DBM-2 + PRP 2
11	2	3	DBM-2 + PRP 3
12	2	4	DBM-2 + PRP 4
13	2	5	DBM-2 + PRP 5
14	2	6	DBM-2 + PRP 6
15		1	PRP 1
16		2	PRP 2
17		3	PRP 3
18		4	PRP 4
19		5	PRP 5
20		6	PRP 6